Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hana Biosciences has completed patient enrollment in its Phase I dose-escalation clinical trial of Alocrest or vinorelbine liposomes injection, Optisome.
Subscribe to our email newsletter
This trial was designed to assess the safety, tolerability and preliminary efficacy of Optisomal encapsulated Alocrest. Preliminary results show that Alocrest was generally well tolerated with acceptable and predictable toxicities and had a maximum tolerated dose comparable to that of un-encapsulated vinorelbine. In this first human study of Alocrest, the drug produced a disease control rate of 46% across a broad range of doses and tumor types.